Self-Funded vs Fully Insured Pharmacy Benefits: Total Cost Comparison for 200–2,000 Employee Companies

Why a $128 PMPM Isn’t Always What It Seems

I once sat across from a CFO at a 600-employee logistics firm who was frustrated by year-over-year pharmacy cost spikes. Their carrier’s report highlighted a “competitive” $128 per member per month (PMPM) pharmacy trend, but a closer look showed specialty drugs like Humira and Ozempic were driving up costs by over 20% from the prior year. The quote for their next renewal arrived with a 17% increase, and there was no real explanation for the number beyond “industry trend.”

Stories like this aren’t rare. Employers between 200 and 2,000 lives see annual pharmacy increases that rarely match what they’re told to expect. Fully insured plans look stable on paper and require little day-to-day management, but they can conceal rising claims, padded with risk charges, taxes, and carrier profit margins. Self-funded pharmacy plans, meanwhile, promise more transparency and data access, but they come with new risks and administrative work. The decision isn’t just about price. It’s about how much control you want, what risks you can stomach, and whether the potential for savings justifies the added complexity.

Breaking Down the Real Cost Differences

On a fully insured model, you’re paying a fixed monthly premium per employee that covers expected claims, carrier admin fees, state-mandated benefits, and a profit margin for the insurer. The upside is predictability, the carrier eats the risk of a bad claims year. For a 400-life professional services firm I worked with last year, their carrier premium was $152 PMPM for pharmacy. That totaled just over $730,000 a year. They never saw a claims report with drug-level detail, just an annual renewal with a percentage increase.

Self-funding is different. You pay the actual claims as they come in, plus a fixed admin fee to a third-party administrator (TPA) or pharmacy benefit manager (PBM), plus stop-loss insurance to cap catastrophic risk. That same 400-life group could project pharmacy claims at $115 PMPM (based on their mix of generics, specialty, and historical trend), with $8 PMPM in admin and $10 PMPM for stop-loss premiums. Now you’re targeting $133 PMPM, about $90,000 lower on an annualized basis than the fully insured premium. But you also take on claims volatility, one new cystic fibrosis patient could drive an unplanned $300,000 in spend unless stop-loss coverage fits well.

In practice, many mid-sized employers with decent claims predictability can expect total pharmacy costs to run 8%-15% lower under a well-managed self-funded plan, especially after a year or two of real data and clinical interventions. The catch: the first year is always a little less predictable, and you’ll spend more time analyzing reports, reviewing stop-loss terms, and making decisions about plan design.

Specialty Drugs, Rebates, and Where the Savings Actually Come From

Fully insured pharmacy premiums roll in both the gross claims and the carrier’s estimate of manufacturer rebates. But those rebates rarely flow directly back to the employer in a transparent way. In self-funded plans, particularly if you use an independent PBM (like Capital Rx, EmpiRx, or Navitus), you can negotiate for pass-through rebates, meaning every rebate dollar goes back to your plan. For a 1,200-employee manufacturing company I worked with, this meant an extra $150,000 credited back to the plan each year versus staying fully insured.

The biggest cost driver for both models now is specialty pharmacy. For most mid-market employers, specialty represents 50-55% of total pharmacy spend even though fewer than 2% of members use these drugs. Drugs like Humira ($6,000/month), Enbrel ($5,200/month), Ozempic ($1,200/month), and Zepbound ($1,000/month) regularly top the spend chart. In fully insured plans, this risk is pooled, but you have no ability to direct patients to lower-cost biosimilars or specialty pharmacy partners. In self-funded models, you can add clinical programs and steer patients to biosimilar adalimumab (Hadlima, Hyrimoz) that run 40-60% cheaper than reference Humira. That can save $350,000 or more a year for a 2,000-life plan with 30+ Humira utilizers, provided your PBM contract supports these switches.

For more granular drug cost benchmarking, I often point teams to RxInfo.ai for real-time pricing and trend data. This helps HR and finance teams see exactly where their biggest cost risks lie, something that’s usually impossible with standard fully insured reporting.

Practical Tradeoffs: Risk, Reporting, and Managing Change

Some HR teams love the idea of self-funding until the first pharmacy report shows a $70,000 claim for a rare cancer drug. On the flip side, I’ve seen employers stuck in fully insured contracts who never realize they’re paying more for the same drugs, sometimes 10-20% over the actual claims cost, because they’re subsidizing the carrier’s block of business. The real question isn’t just, “Which is cheaper?” It’s, “Who is best positioned to manage volatility and make proactive plan design decisions?”

Fully insured is smoothest for companies with fewer than 250 employees, high turnover, or limited HR resources. You don’t need a dedicated pharmacy consultant or a stop-loss broker. But if you’re between 300 and 2,000 lives, have relatively stable headcount, and want more control over your spend, self-funding can open doors to formulary management, transparent reporting, and vendor selection. You’ll need a solid PBM partner, and ideally, a consultant with experience running carve-out pharmacy RFPs and benchmarking contracts (I often recommend starting with data from RxPBM.ai to compare).

One pitfall is underestimating the value of integrated reporting. Self-funded plans give you timely, drug-level claims data. This means you can spot when a member starts a $12,000/month gene therapy (and tee up copay assistance or patient support before stop-loss is breached). Fully insured, you’ll likely get just aggregate reports, sometimes months in arrears.

Switching models, especially moving from fully insured to self-funded, requires careful employee communication. People notice changes to copays, prior authorization, or pharmacy networks. I’ve helped teams draft FAQs and rollout memos to avoid the classic “Why can’t I use my old pharmacy?” headaches. There’s always a learning curve, but when HR is proactive, the member experience doesn’t have to take a hit.

Who Should Seriously Consider Self-Funding, and When Is Fully Insured the Better Bet?

Companies in the 300-2,000 employee range with reasonably stable medical claims, decent cash flow, and a desire for hands-on management of pharmacy costs are most likely to benefit from self-funding. The biggest wins come to those who use transparent PBMs, negotiate for pass-through rebates, and are willing to implement clinical programs targeting high-cost drugs. If your plan can save $80,000 to $120,000 annually versus fully insured premiums, that’s money you can reinvest in richer benefits or lower employee contributions.

Fully insured still makes sense for groups on the smaller end, especially those without expert internal resources or consultant support. The paperwork is lighter, renewals are easier, and cashflow swings are less scary. But keep an eye on year-over-year renewals and ask for detailed claims data every chance you get. If you start to see cost trends outpacing your peer benchmarks (see RxNews.ai for current PMPM and trend data), it might be time to revisit the self-funded conversation.

No model is perfect. But with specialty spend rising fast and pricing transparency improving, mid-size employers who dig into their pharmacy numbers, whether fully insured or self-funded, are the ones who spot savings opportunities first.